The pharmaceutical company Galectin Therapeutics-B (01672) will report in oral presentation format at the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD) that the weight loss effect of ASC36_35 FDC is superior to the combination of eloralintide and tirzepatide based on preclinical data.

The Zhixin Financial News APP reported that Gesypharmaceuticals-B (01672) announced that the Board of Directors will present a brief oral presentation on ASC36_35 FDC, a once-monthly injectable combination formulation of ASC36 (a multi-peptide insulin receptor agonist) and ASC35 (a multi-peptide GLP-1R/GIPR agonist) for the treatment of obesity, at the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy. The preclinical data shows that in diet-induced obesity (DIO) animal models, the drug demonstrated superior weight loss effects compared to the combination of eloralintide and tirzepatide.